摘要
The objective of the study was to systematically evaluate the efficacy and safety of Shenfu injection in the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD).A total of 15 randomized controlled trials involving 1198 patients were included.The results of meta-analysis showed that compared with the control group,the experimental group can improve the total clinical effective rate in AECOPD patients(relative risk=1.15,95%confidence interval[CI][1.09,1.21],P<0.00001),improve the pulmonary function levels:forced expiratory volume in one second(FEV1)(standardized mean difference=1.88,95%CI[0.89,2.88],P=0.0002)and the FEV1/forced vital capacity(FVC)ratio(FEV1/FVC)(mean difference[MD]=3.96,95%CI[2.74,5.19],P<0.00001);improve the arterial blood oxygen partial pressure(MD=6.03,95%CI[4.58,7.48],P<0.00001),and reduce the arterial blood partial pressure of carbon dioxide(MD=-4.59,95%CI[-6.91,-2.26],P=0.00001),and the white blood cell count in pulmonary infection may be improved(MD=-1.16,95%CI[-1.63,-0.68],P<0.00001).The study showed that the efficacy of experimental group in the treatment of AECOPD is better than control group.Due to the limitation of the number and quality of included studies,this conclusion needs more high quality studies to confirm.
基金
funded by the Special Fund for Basic Scientific Research Expenses of Public Welfare Research Institutes at the central level(Z0597)。